Clamor for GSK shingles shot points to bigger profits

LONDON (Reuters) - GlaxoSmithKline is facing "unprecedented" demand for its new shingles vaccine Shingrix, suggesting the product could be a bigger money-spinner than the company and analysts initially thought.